phenyl 3-(benzyloxy)-2-[[(benzyloxy)carbonyl][3-(dimethylamino)-2,2-dimethylpropyl]amino]-6-fluoro-5-methylpyridine-4-carboxylate | 1254367-73-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: phenyl 3-(benzyloxy)-2-[[(benzyloxy)carbonyl][3-(dimethylamino)-2,2-dimethylpropyl]amino]-6-fluoro-5-methylpyridine-4-carboxylate
• 英文别名: Phenyl 2-[[3-(dimethylamino)-2,2-dimethylpropyl]-phenylmethoxycarbonylamino]-6-fluoro-5-methyl-3-phenylmethoxypyridine-4-carboxylate
• CAS: 1254367-73-1
• 化学式: C₃₅H₃₈FN₃O₅
• 分子量: 599.702
• InChiKey: KASZGIYZBFDHFP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.3
• 重原子数：
  44
• 可旋转键数：
  14
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  81.2
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  phenyl 3-(benzyloxy)-2-[[(benzyloxy)carbonyl][3-(dimethylamino)-2,2-dimethylpropyl]amino]-6-fluoro-5-methylpyridine-4-carboxylate 在 四甲基乙二胺 、 氢氟酸 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 水 、 乙腈 为溶剂， 反应 19.17h， 生成
  参考文献：
  名称：

  8-Azatetracyclines: Synthesis and Evaluation of a Novel Class of Tetracycline Antibacterial Agents

  摘要：

  A novel series of fully synthetic 8-azatetracyclines was prepared and evaluated for antibacterial activity. Compounds were identified that overcome both efflux (tet(K)) and ribosomal protection (tet(M)) tetracycline resistance mechanisms and are active against Gram-positive and Gram-negative organisms. Two compounds were identified that exhibit comparable efficacy to marketed tetracyclines in in vivo models of bacterial infection.

  DOI：

  10.1021/jm1015389
• 作为产物：
  描述：

  N,N,2,2-四甲基-1,3-丙二胺 在 tris-(dibenzylideneacetone)dipalladium(0) 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 1.83h， 生成 phenyl 3-(benzyloxy)-2-[[(benzyloxy)carbonyl][3-(dimethylamino)-2,2-dimethylpropyl]amino]-6-fluoro-5-methylpyridine-4-carboxylate
  参考文献：
  名称：

  8-Azatetracyclines: Synthesis and Evaluation of a Novel Class of Tetracycline Antibacterial Agents

  摘要：

  A novel series of fully synthetic 8-azatetracyclines was prepared and evaluated for antibacterial activity. Compounds were identified that overcome both efflux (tet(K)) and ribosomal protection (tet(M)) tetracycline resistance mechanisms and are active against Gram-positive and Gram-negative organisms. Two compounds were identified that exhibit comparable efficacy to marketed tetracyclines in in vivo models of bacterial infection.

  DOI：

  10.1021/jm1015389

文献信息

• [EN] 8-AZA TETRACYCLINE COMPOUNDS<br/>[FR] COMPOSÉS DE 8-AZA TÉTRACYCLINE
  申请人：TETRAPHASE PHARMACEUTICALS INC

  公开号：WO2010129055A1

  公开（公告）日：2010-11-11

  The present invention is directed to a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.

  本发明涉及一种由结构式（I）表示的化合物或其药用盐。结构式I的变量在此定义。还描述了包括结构式I化合物的药物组合物及其治疗用途。
• 8-AZA Tetracycline Compounds
  申请人：Clark Roger B.

  公开号：US20120108569A1

  公开（公告）日：2012-05-03

  The present invention is directed to a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.
• US8367654B2
  申请人：——

  公开号：US8367654B2

  公开（公告）日：2013-02-05
• US8828988B2
  申请人：——

  公开号：US8828988B2

  公开（公告）日：2014-09-09
• 8-Azatetracyclines: Synthesis and Evaluation of a Novel Class of Tetracycline Antibacterial Agents
  作者：Roger B. Clark、Minsheng He、Corey Fyfe、Denene Lofland、William J. O’Brien、Louis Plamondon、Joyce A. Sutcliffe、Xiao-Yi Xiao

  DOI：10.1021/jm1015389

  日期：2011.3.10

  A novel series of fully synthetic 8-azatetracyclines was prepared and evaluated for antibacterial activity. Compounds were identified that overcome both efflux (tet(K)) and ribosomal protection (tet(M)) tetracycline resistance mechanisms and are active against Gram-positive and Gram-negative organisms. Two compounds were identified that exhibit comparable efficacy to marketed tetracyclines in in vivo models of bacterial infection.